Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.
Brutal on share holders
("Novacyt", the "Company" or the "Group")
R&D Update
Significant new opportunities for growth
Paris, France and Camberley, UK - 27 July 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an R&D update.
R&D highlights
· Launch of near-patient (mobile) testing, which comprises Novacyt's COVID-19 test, direct-to-PCR RNA extraction kit (Exsig™ Direct), and q16 and q32 instruments
· Launch of a saliva sampling type to support ease of patient sampling, lower levels of discomfort and demonstrate more reproducible data
· Development of a respiratory testing panel to diagnose and distinguish between influenza A&B, RSV and COVID-19. Launch expected during September 2020 for the 2020/21 flu season in the Northern hemisphere
· Development of a two-gene test to address markets employing this testing approach. Launch expected no later than September 2020
· Development, together with a partner, of a serology (antibody) test to detect past infection of COVID-19. Launch expected in Q4 2020
The Company's COVID-19 polymerase chain reaction (PCR) test was one of the first to be developed and registered under the CE-IVD Directive, establishing Novacyt as a pioneer and a leader in COVID-19 diagnostics. The success of the product has been built around robust design principles and the selection of a gene target that has so far demonstrated exceedingly low levels of genetic mutation and variation. To date, the target has been analysed against 42,655 individual COVID-19 viral sequences and demonstrated 100% detection.
Novacyt remains committed to building on this innovative position for COVID-19 testing, and more broadly for respiratory disease testing, and investing to address unmet needs in the market. The Company has already launched three new innovative products, Exsig™ Direct, Exsig™ Mag and COVID-HT, to support laboratories testing for COVID-19 through improving workflow efficiency and helping to address the reported shortfall in global manufacturing and supply of extraction reagents.
Scientists at the Company continue to innovate and detailed below is an update on the current development activities, which are expected to drive incremental revenue for the Company once launched. Novacyt continues to build on its patent portfolio through new filings to protect its products and market leading position in COVID-19 testing.
Launch of near-patient (mobile) testing
Further to the Company announcement on 22 July 2020, Novacyt confirms the launch of its near-patient testing (NPT) system for COVID-19. Validation of the NPT system includes analysis of over 400 patient samples carried out by a leading, accredited clinical laboratory. The reported sensitivity and specificity are both greater than 99%.
A number of NHS hospitals are already using Novacyt's NPT system in hospital departments. Pilot programmes are underway in surgical, cancer and i
EURASIA MINING PLC
("Eurasia" or "the Company")
Holdings in Company
Eurasia Mining plc, the palladium, platinum, rhodium, iridium and gold producing company, operating the established West Kytlim Mine in the Urals, and also the operator of the Monchetundra Project comprising two predominantly palladium open pit deposits located 3km away from Severonickel, one of Norilsk Nickel's largest base metals and PGM processing facilities, near the town of Monchegorsk on the Kola Peninsula, confirms that Queeld Ventures Limited ("Queeld Ventures") still holds 307,250,000 ordinary shares in the Company representing 11.28% of the issued share capital of the Company, as previously announced on 11 November 2019. According to the information available to the Company, the ultimate beneficial owner of Queeld Ventures is Galina Pchelkina.
Why did this have to be confirmed ?
2,000 patient clinical trial using Novacyt's near-patient testing system initiated in London care homes
Paris, France and Camberley, UK - 22 July 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, notes the initiation of a clinical trial by Queen Mary University of London using the Company's innovative near-patient testing system. The study is investigating whether daily COVID-19 testing reduces the infection rate, morbidity and mortality in the high-risk care home population.
The randomised clinical trial, recruiting up to 2,000 residents in 50 care homes across east London, is being led by Professor Jo Martin, President of the Royal College of Pathologists and Professor of Pathology at Queen Mary University of London. The study is using a mobile or near-patient testing (NPT) system for COVID-19 developed by Novacyt (further detail below), which comprises the Company's COVID-19 polymerase chain reaction (PCR) test, direct-to-PCR RNA extraction kit (exsig™ Direct), and portable testing instruments (Q16 and Q32 instruments), to ensure reliable results are received within an hour of testing.
The clinical trial team comprises researchers, medical students and laboratory experts from Queen Mary and Novacyt. Daily testing, using Novacyt's NPT system, is being trialled for residents, staff and visitors in 25 care homes. As the comparator, the other 25 care homes will receive standard central laboratory testing once a week.
As part of the clinical trial, the effectiveness of mid-nose nasal swabs compared to invasive nasopharyngeal swabs will be evaluated to support ease of use, lower levels of discomfort and demonstrate more reproducible data.
Professor Jo Martin, Professor of Pathology at Queen Mary University of London, and lead investigator of the study, commented:
"This work has the potential to bring a new rapid COVID-19 testing system to those at highest risk and help interrupt community transmission. If found to be successful in care homes, it could be very useful in a wide range of settings, helping to make a quick diagnosis and keep an environment free of COVID-19.
"With rapid daily testing, we can report back to the care home on the same day, so that they can take action to reduce transmission in their care home and prevent outbreaks into the wider community. By undertaking this study in the diverse East London community, we're hoping to protect one of the most vulnerable groups in the UK, and the frontline staff who are caring for them."
Graham Mullis, Group CEO of Novacyt, added:
"We are delighted to be working with Professor Jo Martin and her expert team at Queen Mary University of London to complete this important clinical trial. We believe daily testing with our near-patient testing system, which incorporates the use of our market leading COVID-19 test, has the potential to reduce the transmission of SARS-CoV-2 in the high-risk care home population and in
https://www.londonstockexchange.com/news-article/SNG/holding-s-in-company/14622285